
Mastering Single Best Answer Questions for the Part 2 MRCOG Examination: An Evidence-Based Approach

MOCK EXAMINATION

Answers to Paper 2

1. C. Single-agent intramuscular methotrexate
2. E. It avoids the need for surgery in over 70% of women
3. C. Advise her to involve her parents but endorse her request if two doctors agree that she has sufficient maturity and understanding to appreciate what is involved
4. E. McCune–Albright syndrome
5. A Adrenocorticotrophic hormone (ACTH) stimulation test
6. D. Normal saline
7. D. Re-excision
8. E. Wide local excision with right pelvic nodes dissection
9. D. Endodermal sinus tumour
10. A. Adjuvant chemotherapy
11. A. A 3-month continuous use of combined oral contraceptive pills (COCP) and restart a new 3-month cycle after the end of the withdrawal bleed
12. E. The most common side effects reported after the procedure are pain and vaginal discharge
13. B. Arrange transvaginal scan
14. E. Uterine artery embolization (UAE).
15. D. Transvaginal ultrasound
16. A. 1 in 6
17. B. 4 weeks
18. E. Tolterodine
19. B. More than 15 ml/sec
20. B. Both HBAA and HBAS embryos can be transferred
21. E. The couple should proceed to IVF as soon as possible
22. E. He should wait for a further 2 months before they can start fertility treatment

23. A. Late age at menarche and first pregnancy increase the incidence of breast cancer
24. B. Battery
25. C. Consider breastfeeding prior to taking the lamotrigine dose
26. D. Negative thyroid receptor antibody titre
27. B. 5%
28. D. Stage 3
29. B. Semen washing and artificial insemination is a safe option for both female partner and offspring
30. B. Stage 2
31. D. Vaginal 600 mcg of misoprostol
32. A. Ultrasound scan within 4–7 days
33. B. Class this as a never event
34. E. Choose a topic that meets the auditable standards of the College guidelines
35. D. Discontinue the method and offer a more suitable option
36. B. Ella One (30 mg micronized ulipristal acetate)
37. E. The copper intrauterine device
38. E. Transvenous embolization of ovarian vein
39. A. A 50% likelihood of an affected male offspring and a healthy female carrier
40. D. No pharmacotherapy is required
41. D. Should continue with this method
42. A. Azithromycin 1 g/week orally for 2 weeks plus ceftriaxone 500 mg intramuscular stat dose
43. D. The Data Protection Act, the Abortion Act and the Mental Capacity Act
44. D. *N. gonorrhoea*
45. E. VIN associated with lichen sclerosis
46. B. Lichen sclerosis
47. B. Radiotherapy
48. D. Outpatient office hysteroscopy and biopsy
49. D. Cyclic combined oral contraceptive pill
50. D. B3 adrenoceptor agonist